Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Combined Biopsy Beats Target Biopsy for Prostate Cancer Detection

Key clinical point: The rate of clinically significant prostate cancer detection was highest using combined biopsy compared with target biopsy or standard practice biopsy alone.

Major finding: Combined biopsy, target biopsy, and standard practice biopsy detection rates were 38%, 30%, and 26%, respectively.

Study details: The data come from a review of 404 patients with clinical suspicion of prostate cancer.

Disclosures: The researchers had no financial conflicts to disclose.

Citation:

DemirtaƟ T et al. Cureus. 2020. doi: 10.7759/cureus.6160.